Photo from wikipedia
BMT CTN 0901 enrolled patients with MDS (N=54) or AML (N=218) (median age of 55 years) who had Overall survival (OS) at 4 years was 65% and 49% for MAC… Click to show full abstract
BMT CTN 0901 enrolled patients with MDS (N=54) or AML (N=218) (median age of 55 years) who had Overall survival (OS) at 4 years was 65% and 49% for MAC and RIC (p=0.02), respectively. In multivariate analysis of overall mortality, the hazard ratio (HR) for death was 1.54 (95% Confidence Interval [CI] 1.07-2.20, p=0.02) for RIC compared to MAC. Other risk factors for mortality were protocol-defined high risk disease (HR 1.77) and age of ≥50 ys (HR 2.20). RFS rates at 4 years was 58% and 34% for MAC and RIC (p Long term follow up of MAvRIC showed longer survival for MAC recipients. Thus, this trial confirms the importance of intensity for HCT; for patients eligible for either intensity regimen, MAC is the superior choice.
Journal Title: Biology of Blood and Marrow Transplantation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!